Form 4: Processa Pharmaceuticals Executive Sian Bigora Reports Stock Transactions Following Reverse Stock Split

Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units, adjusted for a recent 20-to-1 reverse stock split.

Summary

• Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report includes transactions from January 1, 2024, involving common stock and restricted stock units.
• A distribution of 1,675 vested restricted shares occurred.
• The reported securities amounts have been adjusted to reflect a 20-to-1 reverse stock split that took effect on January 22, 2024.
• Following the reported transactions, Bigora directly owns 21,458 shares of common stock and indirectly owns 6,668 shares through CorLyst, LLC.
• She also directly owns 22,139 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about insider transactions.
• The reverse stock split impacts the number of shares held by all shareholders.

Key Dates

Keywords

Form 4, Processa Pharmaceuticals, Sian Bigora, reverse stock split, beneficial ownership, stock transactions, restricted stock units, common stock